Sector News

UK books COVID-19 vaccine doses from J&J and Novavax and backs new clinical trials

August 17, 2020
Life sciences

There are still plenty of questions swirling around the leading COVID-19 vaccine candidates, including how many doses might be needed to ensure protection against the virus and, of course, which will ultimately succeed in clinical trials. Judging from the United Kingdom’s most recent deals, the government is determined to cover all its bases.

The U.K. unveiled two new agreements Friday, one with Novavax for 60 million doses of its COVID vaccine candidate, and another with Johnson & Johnson’s Janssen unit for 30 million doses of its shot. If they succeed in clinical trials, the vaccines could be delivered to the U.K. by mid-2021, the government said.

The region’s potential stockpile is now up to 340 million doses from six different companies. If they all work, that would be enough for everyone in the U.K. to get five inoculations, several press outlets calculated.

The Novavax and J&J deals have research components, too. The U.K. government will support a phase 3 trial of Novavax’s candidate, NVX-CoV2373, which will enroll 9,000 adults starting in the third quarter. The financial terms of the deal were not disclosed, though Novavax did agree to expand its partnership with Fujifilm’s Diosynth Biotechnologies to manufacture one component of the vaccine in the U.K.

Kate Bingham, chair of the U.K. government’s vaccines task force, deemed Novavax’s most recent clinical trial results “encouraging” in that the protein-based vaccine “triggers an immune response greater than that in patients who have recovered from the disease,” she said in a statement.

Novavax hasn’t drawn as much attention as bigger players in the COVID-19 vaccine race, but it has been turning heads lately. The biotech’s executives told investors on a recent conference call that the company will have enough manufacturing capacity to meet demand in the U.S. starting in 2021, when it will be able to make more than one billion doses a year.

In a note to investors earlier this week, Evercore ISI analysts predicted Novavax would claim 20% of the market for COVID-19 vaccines, outpaced only by Moderna.

Under the U.K. government’s new deal, J&J will supply 30 million doses of its COVID vaccine candidate, Ad26.COV2.S, “on a not-for-profit basis for emergency pandemic use,” the company said in a statement (PDF).

J&J is also expanding its research agreement with the U.K. by launching a new phase 3 study of a two-dose regimen of Ad26.COV2.S. A phase 3 study of a single dose is already underway in the U.K..

“The sooner we start the two-dose study of the Janssen vaccine, the sooner we will know whether the vaccine can provide durable, long-term protection against COVID-19 infection,” Bingham said.

The one-versus-two-dose question is an important one for J&J. The company’s research collaborators at Beth Israel Deaconess Medical Center in Boston showed in both animal and human trials that giving a second shot of Ad26.COV2.S boosts the antibody response to COVID-19 by tenfold. J&J is now testing both regimens in the U.S.

J&J is lagging behind Moderna and other COVID-19 vaccine developers in the race to approval, but its candidate has garnered some enthusiasm, largely because the technology used to create it has a track record. About 60,000 people have been inoculated against Ebola with a vaccine J&J developed using the same technology behind Ad26.COV2.S.

J&J recently struck a $1 billion deal with the U.S. to supply 100 million doses of Ad26.COV2.S, and the company said Thursday it’s in talks with the European Union to contribute 200 million doses to its stockpile.

By: Arlene Weintraub

Source: Fierce Pharma

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend